Woodside, Darren G.,Vanderslice, Peter,Marathi, Upendra K.
申请号：
AU2016254034
公开号：
AU2016254034A1
申请日:
2016.04.28
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which maybe used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions. Compositions and methods including the mimetics enhance: (1) the priming of vaccines (including, but not limited to, cancer vaccines)； (2) cytolytic activity of adoptive cell therapies (including, but not limited to ϒδΤ-cells, CTLs, NK, iNKT)； (3) immunotherapies (including, but not limited to, negative checkpoint blockage strategies such as anti- CTLA-4 and anti-PD-1)； and (4) biologic therapies (including, but not limited, to trastuzumab and rituxamab), whereby the mechanism-of-action includes antibody dependent cellular cytotoxicity (ADCC).
